Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
B 96.04 -2.04% -2.00
GILD closed down 2.04 percent on Friday, February 7, 2025, on 1.11 times normal volume.
9 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup -2.04%
Overbought Stochastic Strength -2.04%
New 52 Week Closing High Bullish -3.62%
Pocket Pivot Bullish Swing Setup -3.62%
New 52 Week High Strength -3.62%
Upper Bollinger Band Walk Strength -3.62%
Earnings Movers Other -3.62%
Multiple of Ten Bearish Other -3.62%
Gapped Up Strength -3.62%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biopharmaceutical Nasdaq 100 Disease Inflammation Infection Hypertension Cardiovascular Disease Antibiotics Coronavirus Influenza Vascular Disease Macular Degeneration Liver Disease Respiratory Diseases Cystic Fibrosis HIV Pulmonary Arterial Hypertension Immunodeficiency Perfusion Oligonucleotide Organic Chemistry Hepatotoxins Angina Retinitis Gilead Sciences Prodrugs Treatment Of Cardiovascular Disease Cytomegalovirus Retinitis Fungal Infection Fungal Infections Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil Treatment Of Cardiovascular Diseases

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 100.51
52 Week Low 60.2439
Average Volume 6,493,563
200-Day Moving Average 79.46
50-Day Moving Average 92.82
20-Day Moving Average 94.39
10-Day Moving Average 96.90
Average True Range 1.95
RSI (14) 55.36
ADX 35.32
+DI 30.75
-DI 13.60
Chandelier Exit (Long, 3 ATRs) 94.66
Chandelier Exit (Short, 3 ATRs) 94.42
Upper Bollinger Bands 100.17
Lower Bollinger Band 88.60
Percent B (%b) 0.64
BandWidth 12.25
MACD Line 1.67
MACD Signal Line 1.37
MACD Histogram 0.302
Fundamentals Value
Market Cap 119.69 Billion
Num Shares 1.25 Billion
EPS 0.09
Price-to-Earnings (P/E) Ratio 1067.11
Price-to-Sales 4.32
Price-to-Book 6.48
PEG Ratio 0.56
Dividend 3.06
Dividend Yield 3.19%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 99.69
Resistance 3 (R3) 100.04 99.19 99.08
Resistance 2 (R2) 99.19 98.26 99.01 98.87
Resistance 1 (R1) 97.61 97.68 97.19 97.26 98.67
Pivot Point 96.76 96.76 96.54 96.58 96.76
Support 1 (S1) 95.18 95.83 94.76 94.83 93.41
Support 2 (S2) 94.33 95.25 94.15 93.21
Support 3 (S3) 92.75 94.33 93.00
Support 4 (S4) 92.40